SEP 8, 2026 · PHASE 3 TRIAL
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
ClinicalTrials.gov
This is a clinical trial registry record describing a planned Phase 3 study with no results reported; it documents study design and enrollment targets only.
Reported
Planned enrollment1264
Primary endpoint (Part A and B)Progression-Free Survival, randomization to…
Primary endpoint timeframeapproximately 1 year